Table 6 Studies in non-Asian countries with atropine 0.01% and 2-years follow-up.
Author, year | Country, n (C:Control/A: Atropine) | Study design | Age (years) (range, mean, SD) | Baseline SE (D) (range, mean, SD/IC95) | Baseline AL (mm) (mean, SD/IC95) | Follow-up time (months) | Change of SE (D) (mean) | Control rate of SE progression (dif D, %) | Change of AL (mm) (mean)* | Control rate of AL progression (dif mm, %) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Range | Control | Atropine 0.01% | Range | Control | Atropine 0.01% | Control | Atropine 0.01% | Control | Atropine 0.01% | Control | Atropine 0.01% | ||||||
Larkin, 2019 | USA (C:98/A:100) | Retro | 6–15 | 9 | 9 | − 0.25 to − 8.00 | − 2.8 (1.6) | − 2.8 (1.6) | 0–12 | − 0.6 | − 0.2 | 0.40 (66.7) | |||||
12–24 | − 0.6 | − 0.1 | 0.50 (83.3) | ||||||||||||||
0–24 | − 1.2 | − 0.3 | 0.90 (75) | ||||||||||||||
Moriche-Carretero, 2021 | Spain (C: 168/A:171) | RCT | 5–11 | 7.24 (1.77) | 7.37 (1.54) | − 1.25 to − 4.25 | − 2.16 (0.62) | − 2.13 | 24.26 (0.91) | 24.22 (0.66) | 0–24 | − 0.76 | − 0.51 | 0.25 (32.8) | 0.37 | 0.20 | 0.17 (45.9) |
Lee S, 2022 | Australia (C: 49/A104) | RCT | 6–16 | 12.2 (2.5) | 11.2 (2.7) | ≤ − 1.50 | − 3.56 (− 4.56, − 2.75) | − 3.13 (− 4.08, − 2.48) | 24.7 (24.4, 25.4) | 24.6 (24.2, 25.2) | 0–12 | − 0.53 | − 0.31 | 0.22 (41.5) | 0.25 | 0.16 | 0.09 (36) |
12–24 | − 0.25 | − 0.33 | 0.62 | 0.36 | 0.26 (41.9) | ||||||||||||
0–24 | − 0.78 | − 0.64 | 0.14 (18.9) | 0.38 | 0.34 | 0.04 (10.5) | |||||||||||
Zadnik K, 2023 CHAMP | USA, UK, Spain, Hungary, Netherlands, Ireland (C: 165/A: 164) | RCT, Multic | 3–17 | − 0.50 to − 6.00 | − 3.72 (1.42) | − 3.41 (1.49) | 24.33 (0.84) | 24.37 (0.81) | 0–12 | − 0.57 | − 0.45 | 0.12 (21) | 0.37 | 0.30 | 0.07 (18.9) | ||
12–24 | − 0.43 | − 0.34 | 0.09 (20.9) | 0.26 | 0.21 | 0.05 (19.2) | |||||||||||
0–24 | − 1 | − 0.79 | 0.21 (21) | 0.63 | 0.51 | 0.12 (19) | |||||||||||
Perez Flores, 2023 GTAM | Spain (A: 105) | Prospec, Multic | 6–14 | 9.74 (1.90) | − 2.00 to − 6.00 | − 3.57 (1.12) | 24.56 (0.75) | 0–12 | − 0.42 | 0.25 | |||||||
12–24 | − 0.45 | 0.24 | |||||||||||||||
0–24 | − 0.88 | 0.49 | |||||||||||||||
